OncoMatch

OncoMatch/Clinical Trials/NCT04643366

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Is NCT04643366 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy for rectal cancer.

Phase 2RecruitingVirginia Commonwealth UniversityNCT04643366Data as of May 2026

Treatment: ChemotherapyThis is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Required: Stage T3-4 N0 M0, T ANY N1-2 M0 (AJCC 8th ed.)

Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: radiation therapy

Exception: Prior RT that would result in unsafe overlap of RT fields with the planned study treatment, per the treating radiation oncologist

Prior RT that would result in unsafe overlap of RT fields with the planned study treatment, per the treating radiation oncologist

Cannot have received: 5-fluorouracil, leucovorin, or oxaliplatin (5-fluorouracil, leucovorin, oxaliplatin)

Exception: Prior known allergic reaction

Prior known allergic reaction to 5-fluorouracil, leucovorin, or oxaliplatin

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥ 1,200 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL (transfusion/intervention allowed to achieve Hgb ≥8.0 g/dL)

Kidney function

Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft-Gault formula

Liver function

AST and alkaline phosphatase < 2.5 x upper limit of normal (ULN); Bilirubin ≤ 2.5 ULN

Adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,200 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb ≥8.0 g/dL is acceptable.) Adequate liver and renal function defined as follows: AST and alkaline phosphatase < 2.5 x upper limit of normal (ULN); Bilirubin ≤ 2.5 ULN; Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft-Gault formula

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Virginia Cancer Institute · Richmond, Virginia
  • Virginia Commonwealth University Massey Cancer Center · Richmond, Virginia
  • VCU Community Memorial Healthcenter · South Hill, Virginia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify